Ignite Creation Date:
2025-12-25 @ 4:29 AM
Ignite Modification Date:
2025-12-26 @ 3:32 AM
Study NCT ID:
NCT06945120
Status:
RECRUITING
Last Update Posted:
2025-11-13
First Post:
2025-04-18
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
ACT Lung Health Intervention: Phase Two
Sponsor:
Dana-Farber Cancer Institute
Organization:
Study Overview
Official Title:
Efficacy of an Asian Culture-tailored Lung Health (ACT) Intervention on Lung Cancer Screening and Smoking Cessation in Asian Americans
Status:
RECRUITING
Status Verified Date:
2025-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer.
Detailed Description:
This two-arm stratified randomized clinical trial is to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer.
Participants will be randomized into one of two groups: Group A: ACT Lung Health Intervention versus Group B: Standard Care. Randomization means a participant is placed into a study group by chance.
The research study procedures include screening for eligibility, questionnaires, and saliva tests.
It is expected participation in this study will last about 6 months.
About 60 participants are expected to take part in this research study.
The National Cancer Institute is providing funding for this trial.
Participants will be randomized into one of two groups: Group A: ACT Lung Health Intervention versus Group B: Standard Care. Randomization means a participant is placed into a study group by chance.
The research study procedures include screening for eligibility, questionnaires, and saliva tests.
It is expected participation in this study will last about 6 months.
About 60 participants are expected to take part in this research study.
The National Cancer Institute is providing funding for this trial.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 5U54CA156734-14 | NIH | None | https://reporter.nih.gov/quic… | View |
| 5U54CA156732-14 | NIH | None | https://reporter.nih.gov/quic… | View |